Participates in cell migration, regulates cell adhesion. High CD87 expression correlates with poor clinical outcome and significantly shorter overall survival in SCLC. CD87+ cell population demonstrated a high spherical ability, an increased tumor initiation potential, and significant resistance to traditional chemotherapeutic agents in SCLC therapy (Romer et al., 2004; Gutova et al., 2007; Almasi et al., 2013; Kubo et al., 2013; Codony-Servat et al., 2016; MacDonagh et al., 2017). The gene discussed is PLAUR; the disease is neoplasm.